Targeting the telomere and shelterin complex for cancer therapy: Current views and future perspectives

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 2, 2011, Pages 179-186

  Bilsland, Alan E ^a   Cairney, Claire J ^a   Nicol Keith, W ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cancer; Novel therapeutics; Senescence; Shelterin; Targeting; Telomerase; Telomere; Telosome

Indexed keywords

ENZYME INHIBITOR; SHELTERIN, HUMAN; TELOMERASE; TELOMERE BINDING PROTEIN;

APOPTOSIS; CELL AGING; DNA DAMAGE; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; REVIEW; TELOMERE; TELOMERE HOMEOSTASIS;

APOPTOSIS; CELL AGING; DNA DAMAGE; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TELOMERASE; TELOMERE; TELOMERE HOMEOSTASIS; TELOMERE-BINDING PROTEINS;

EID: 79951926043     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01253.x     Document Type: Review

References (66)

1. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009; 28: S24-31.
2. Keith WN, Bilsland AE. Targeting telom-erase: therapeutic options for cancer treatment. In: Rudolph KL, editor. Telomeres and telomerase in ageing, disease, and cancer. Berlin: Springer-Verlag; 2008. pp. 247-283.
3. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet. 2008; 42: 301-34.
4. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer. 2008; 8: 167-79.
5. Folini M, Brambilla C, Villa R, et al Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur J Cancer. 2005; 41: 624-34.
6. Folini M, Gandellini P, Zaffaroni N. Targeting the telosome: therapeutic implications. Biochim Biophys Acta. 2009; 1792: 309-16.
7. De Cian A, Lacroix L, Douarre C, et al argeting telomeres and telomerase. Biochimie. 2008; 90: 131-55.
8. Lipps HJ, Rhodes D. G-quadruplex structures: in vivo evidence and function. Trends Cell Biol. 2009; 19: 414-22.
9. Pedroso IM, Hayward W, Fletcher TM. The effect of the TRF2 N-terminal and TRFH regions on telomeric G-quadruplex structures. Nucleic Acids Res. 2009; 37: 1541-54.
10. Sun D, Thompson B, Cathers BE, et al Inhibition of human telomerase by a G-quadruplex-interactive compound. J Med Chem. 1997; 40: 2113-6.
11. Harrison RJ, Cuesta J, Chessari G, et al Trisubstituted acridine derivatives as potent and selective telomerase inhibitors. J Med Chem. 2003; 46: 4463-76.
12. Burger AM, Dai F, Schultes CM, et al The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res. 2005; 65: 1489-96.
13. Gowan SM, Harrison JR, Patterson L, et al A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol. 2002; 61: 1154-62.
14. Incles CM, Schultes CM, Kempski H, et al A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells. Mol Cancer Ther. 2004; 3: 1201-6.
15. Taetz S, Murdter TE, Zapp J, et al Decomposition of the telomere-targeting agent BRACO19 in physiological media results in products with decreased inhibitory potential. Int J Pharm. 2008; 357: 6-14.
16. Cookson JC, Heald RA, Stevens MF. Antitumor polycyclic acridines. 17. Synthesis and pharmaceutical profiles of pentacyclic acridinium salts designed to destabilize telomeric integrity. J Med Chem. 2005; 48: 7198-207.
17. Gowan SM, Heald R, Stevens MF, et al Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. Mol Pharmacol. 2001; 60: 981-8.
18. Cookson JC, Dai F, Smith V, et al Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3, 11-diflu-oro-6, 8, 13-trimethyl-8H-quino[4, 3, 2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. Mol Pharmacol. 2005; 68: 1551-8.
19. Leonetti C, Scarsella M, Riggio G, et al G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors. Clin Cancer Res. 2008; 14: 7284-91.
20. Salvati E, Leonetti C, Rizzo A, et al Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J Clin Invest. 2007; 117: 3236-47.
21. Cheng MK, Modi C, Cookson JC, et al Antitumor polycyclic acridines. 20. Search for DNA quadruplex binding selectivity in a series of 8, 13-dimethylquino[4, 3, 2-kl] acridinium salts: telomere-targeted agents. J Med Chem. 2008; 51: 963-75.
22. Kristensen JL. Synthesis of RHPS4 via an anionic ring closing cascade. Tetrahedron Letters. 2008; 49: 2351-2354.
23. Kim MY, Vankayalapati H, Shin-Ya K, et al Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. J Am Chem Soc. 2002; 124: 2098-9.
24. Binz N, Shalaby T, Rivera P, et al Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells. Eur J Cancer. 2005; 41: 2873-81.
25. Tauchi T, Shin-ya K, Sashida G, et al Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene. 2006; 25: 5719-25.
26. Tauchi T, Shin-Ya K, Sashida G, et al Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene. 2003; 22: 5338-47.
27. Deeley J, Bertram A, Pattenden G. Novel polyoxazole-based cyclopeptides from Streptomyces sp. Total synthesis of the cyclopeptide YM-216391 and synthetic studies towards telomestatin. Org Biomol Chem. 2008; 6: 1994-2010.
28. Doi T, Yoshida M, Shin-ya K, et al Total synthesis of (R)-telomestatin. Org Lett. 2006; 8: 4165-7.
29. Tera M, Lida K, Ishizuka H, et al Synthesis of a potent G-quadruplex-binding macrocyclic heptaoxazole. Chembiochem. 2009; 10: 431-5.
30. Henson JD, Neumann AA, Yeager TR, et al Alternative lengthening of telomeres in mammalian cells. Oncogene. 2002; 21: 598-610.
31. Rizzo A, Salvati E, Porru M, et al Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway. Nucleic Acids Res. 2009; 37: 5353-64.
32. Temime-Smaali N, Guittat L, Sidibe A, et al The G-quadruplex ligand telomestatin impairs binding of topoisomerase IIIalpha to G-quadruplex-forming oligonucleotides and uncaps telomeres in ALT cells. PLoS ONE. 2009; 4: e6919.
33. Gunaratnam M, Greciano O, Martins C, et al Mechanism of acridine-based telom-erase inhibition and telomere shortening. Biochem Pharmacol. 2007; 74: 679-89.
34. Tahara H, Shin-Ya K, Seimiya H, et al G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells. Oncogene. 2006; 25: 1955-66.
35. Chen Y, Yang Y, van Overbeek M, et al A shared docking motif in TRF1 and TRF2 used for differential recruitment of telomeric proteins. Science. 2008; 319: 1092-6.
36. Xin H, Liu D, Wan M, et al TPP1 is a homologue of ciliate TEBP-beta and interacts with POT1 to recruit telomerase. Nature. 2007; 445: 559-62.
37. Poulet A, Buisson R, Faivre-Moskalenko C, et al TRF2 promotes, remodels and protects telomeric Holliday junctions. EMBO J. 2009; 28: 641-51.
38. Amiard S, Doudeau M, Pinte S, et al A topological mechanism for TRF2-enhanced strand invasion. Nat Struct Mol Biol. 2007; 14: 147-54.
39. Seimiya H, Muramatsu Y, Ohishi T, et al Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell. 2005; 7: 25-37.
40. Smogorzewska A, van Steensel B, Bianchi A, et al Control of human telomere length by TRF1 and TRF2. Mol Cell Biol. 2000; 20: 1659-68.
41. Loayza D, De Lange T. POT1 as a terminal transducer of TRF1 telomere length control. Nature. 2003; 423: 1013-8.
42. Abreu E, Aritonovska E, Reichenbach P, et al TIN2-tethered TPP1 recruits human telomerase to telomeres in vivo. Mol Cell Biol. 2010; 30: 2971-82.
43. Wang F, Podell ER, Zaug AJ, et al The POT1-TPP1 telomere complex is a telomerase processivity factor. Nature. 2007; 445: 506-10.
44. Denchi EL, de Lange T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature. 2007; 448: 1068-71.
45. Guo X, Deng Y, Lin Y, et al Dysfunctional telomeres activate an ATM-ATR-dependent DNA damage response to suppress tumorigenesis. EMBO J. 2007; 26: 4709-19.
46. Kim SH, Davalos AR, Heo SJ, et al Telomere dysfunction and cell survival: roles for distinct TIN2-containing complexes. J Cell Biol. 2008; 181: 447-60.
47. Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene. 2008; 27: S149-57.
48. Brenke R, Kozakov D, Chuang GY, et al Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinformatics. 2009; 25: 621-7.
49. Zeng Z, Wang W, Yang Y, et al Structural basis of selective ubiquitination of TRF1 by SCFFbx4. Dev Cell. 2010; 18: 214-25.
50. Bilsland AE, Hoare S, Stevenson K, et al Dynamic telomerase gene suppression via network effects of GSK3 inhibition. PLoS ONE. 2009; 4: e6459.
51. Dong W, Wang L, Chen X, et al Upregulation and CpG Island hypomethy-lation of the TRF2 gene in human gastric cancer. Dig Dis Sci. 2010; 55: 997-1003.
52. Ning H, Li T, Zhao L, et al TRF2 promotes multidrug resistance in gastric cancer cells. Cancer Biol Ther. 2006; 5: 950-6.
53. Kim MM, Rivera MA, Botchkina IL, et al A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation. Proc Natl Acad Sci USA. 2001; 98: 7982-7.
54. Goldkorn A, Blackburn EH. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res. 2006; 66: 5763-71.
55. Guiducci C, Cerone MA, Bacchetti S. Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability. Oncogene. 2001; 20: 714-25.
56. Li S, Rosenberg JE, Donjacour AA, et al Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res. 2004; 64: 4833-40.
57. Marusic L, Anton M, Tidy A, et al Reprogramming of telomerase by expression of mutant telomerase RNA template in human cells leads to altered telomeres that correlate with reduced cell viability. Mol Cell Biol. 1997; 17: 6394-401.
58. Carden CP, Sarker D, Postel-Vinay S, et al Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discov Today. 2010; 15: 88-97.
59. Damm K, Hemmann U, Garin-Chesa P, et al A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 2001; 20: 6958-68.
60. Pascolo E, Wenz C, Lingner J, et al Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucle-osidic drug candidate. J Biol Chem. 2002; 277: 15566-72.
61. Cristofari G, Reichenbach P, Regamey PO, et al Low- to high-throughput analysis of telomerase modulators with Telospot. Nat Methods. 2007; 4: 851-3.
62. Stohr BA, Blackburn EH. ATM mediates cytotoxicity of a mutant telomerase RNA in human cancer cells. Cancer Res. 2008; 68: 5309-17.
63. Lee TH, Tun-Kyi A, Shi R, et al Essential role of Pin1 in the regulation of TRF1 stability and telomere maintenance. Nat Cell Biol. 2009; 11: 97-105.
64. Wu ZQ, Yang X, Weber G, et al Plk1 phosphorylation of TRF1 is essential for its binding to telomeres. J Biol Chem. 2008; 283: 25503-13.
65. Gomez D, O'Donohue MF, Wenner T, et al The G-quadruplex ligand telomestatin inhibits POT1 binding to telomeric sequences in vitro and induces GFP-POT1 dissociation from telomeres in human cells. Cancer Res. 2006; 66: 6908-12.
66. Krutilina RI, Oei S, Buchlow G, et al A negative regulator of telomere-length protein trf1 is associated with interstitial (TTAGGG)n blocks in immortal Chinese hamster ovary cells. Biochem Biophys Res Commun. 2001; 280: 471-5.